114 related articles for article (PubMed ID: 3093292)
1. [Inhibitory effect of prolactin secretion by luteinizing hormone releasing hormone agonist (buserelin)].
Inoue T; Matsuoka R; Mori H; Kigawa T
Nihon Naibunpi Gakkai Zasshi; 1986 Jun; 62(6):745-53. PubMed ID: 3093292
[TBL] [Abstract][Full Text] [Related]
2. Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis.
Kiesel L; Sandow J; Bertges K; Jerabek-Sandow G; Trabant H; Runnebaum B
J Clin Endocrinol Metab; 1989 Jun; 68(6):1167-73. PubMed ID: 2498387
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
4. Studies on GnRH agonist suppression of estrogen production in patients with endometriosis.
Ohtsuka S; Terakawa N; Shimizu I; Sakata M; Mizutani T; Miyake A; Tanizawa O; Aono T
Endocrinol Jpn; 1989 Aug; 36(4):611-9. PubMed ID: 2510993
[TBL] [Abstract][Full Text] [Related]
5. [Androgens and other hormones in buserelin therapy].
Fuchs U; Zwirner M
Geburtshilfe Frauenheilkd; 1991 Feb; 51(2):140-2. PubMed ID: 1904040
[TBL] [Abstract][Full Text] [Related]
6. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
Kuhl H; Jung C; Taubert HD
Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
[TBL] [Abstract][Full Text] [Related]
7. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
8. LH-RH agonist (buserelin): treatment of endometriosis. Clinical, laparoscopic, endocrine and metabolic evaluation.
Cirkel U; Schweppe KW; Ochs H; Hanker JP; Schneider HP
Arch Gynecol Obstet; 1989; 246(3):139-51. PubMed ID: 2515811
[TBL] [Abstract][Full Text] [Related]
9. Treatment of estrogen-dependent gynecological disorders with the gonadotropin releasing hormone agonist buserelin.
Biberoglu K; Gursoy R; Yildiz A
Gynecol Endocrinol; 1991 Jun; 5(2):109-22. PubMed ID: 1833953
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis.
Lemay A; Maheux R; Huot C; Blanchet J; Faure N
Am J Obstet Gynecol; 1988 Feb; 158(2):233-6. PubMed ID: 3124618
[TBL] [Abstract][Full Text] [Related]
11. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
Lemay A; Quesnel G
Fertil Steril; 1982 Sep; 38(3):376-9. PubMed ID: 6214431
[TBL] [Abstract][Full Text] [Related]
12. Desensitization of the pituitary gland induced in vivo by luteinizing hormone-releasing hormone (LRH) or by the LRH-analogue buserelin does not affect the autonomous secretion of luteinizing hormone and follicle stimulating hormone as observed in vitro.
Schuiling GA; Moes H; Koiter TR
Acta Endocrinol (Copenh); 1984 Aug; 106(4):454-8. PubMed ID: 6433611
[TBL] [Abstract][Full Text] [Related]
13. Blockade of LH and FSH secretion by LH-releasing hormone, by the LH-releasing hormone analogue, buserelin, and by combined treatment with LH-releasing hormone and oestradiol benzoate.
Schuiling GA; Pols-Valkhof N; van der Schaaf-Verdonk GC; Koiter TR
J Endocrinol; 1984 Dec; 103(3):301-9. PubMed ID: 6438265
[TBL] [Abstract][Full Text] [Related]
14. [Successful treatment of endometriosis in women with continuous subcutaneous infusion of gonadotropin-releasing hormone agonist (GnRH-A)].
Masaoka K; Kitazawa M; Kumasaka T
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):405-11. PubMed ID: 2501437
[TBL] [Abstract][Full Text] [Related]
15. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N; Bastide A
Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
[TBL] [Abstract][Full Text] [Related]
16. Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phase.
Lemay A; Metha AE; Tolis G; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1983 May; 39(5):668-73. PubMed ID: 6404661
[TBL] [Abstract][Full Text] [Related]
17. Suppression in the secretion of follicle-stimulating hormone and luteinizing hormone, and ovarian follicle development in heifers continuously infused with a gonadotropin-releasing hormone agonist.
Gong JG; Campbell BK; Bramley TA; Gutierrez CG; Peters AR; Webb R
Biol Reprod; 1996 Jul; 55(1):68-74. PubMed ID: 8793060
[TBL] [Abstract][Full Text] [Related]
18. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
Lemay A; Maheux R; Faure N; Jean C; Fazekas AT
Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
[TBL] [Abstract][Full Text] [Related]
19. Dose-related inhibition of acute luteinizing hormone response during luteinizing hormone-releasing hormone agonist treatment for uterine leiomyoma.
Maheux R; Lemay A; Turcot-Lemay L
Am J Obstet Gynecol; 1988 Feb; 158(2):361-4. PubMed ID: 3124621
[TBL] [Abstract][Full Text] [Related]
20. Long-term suppression of ovarian function by a luteinizing-hormone releasing hormone agonist implant in patients with endometriosis.
Fraser HM; Sandow J; Cowen GM; Lumsden MA; Haining R; Smith SK
Fertil Steril; 1990 Jan; 53(1):61-8. PubMed ID: 2104808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
